Compugen to Release Third Quarter 2020 Results on Thursday, November 5, 2020
Compugen Ltd. (Nasdaq: CGEN) announced it will release its third quarter 2020 financial results on November 5, 2020, before U.S. markets open. A conference call will take place at 8:30 AM ET to review the results and provide corporate updates. Compugen is a leader in cancer immunotherapy, with products like the first-in-class anti-PVRIG antibody COM701 under Phase 1 study, along with COM902 targeting TIGIT. The company focuses on predictive target discovery for therapeutics in immuno-oncology.
- Lead product candidate COM701 is in Phase 1 clinical study.
- Second product candidate COM902 also in Phase 1 clinical study.
- Focus on predictive computational platforms enhances drug discovery.
- None.
HOLON, Israel, Oct. 22, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2020 financial results on Thursday, November 5, 2020 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.
To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0610 internationally. The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. The Company's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. The Company is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.
Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124
Investor Relations contact:
Bob Yedid
LifeSci Advisors, LLC
Email: bob@lifesciadvisors.com
Tel: +1 (646) 597-6989
Media contact:
Josephine Belluardo, Ph.D.
LifeSci Communications
Email: jo@lifescicomms.com
Tel: +1 (646) 751-4361
View original content:http://www.prnewswire.com/news-releases/compugen-to-release-third-quarter-2020-results-on-thursday-november-5-2020-301157835.html
SOURCE Compugen Ltd.
FAQ
When will Compugen release its third quarter 2020 results?
What time is the conference call for Compugen's Q3 results?
What is the ticker symbol for Compugen Ltd.?
What are Compugen's lead product candidates?
